Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

A non-opioid pain medication made by Vertex Pharmaceuticals ... safe and effective alternatives to opioids for pain management." Vertex said that almost 10% of patients initially given opioids ...

we have the opportunity to change the paradigm of acute pain management and establish a new standard of care,” Vertex’s chief executive, Reshma Kewalramani, said in a statement. Soon after the ...

Vertex’s medicine could therefore be an “amazing” addition, he said, as it may offer some relief not only after surgery, but in everyday pain management as well. Journavx might dull ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

Vertex's Chronic Pain Ambitions Hit Roadblock with LSR Data So much of Journavx's potential lies in chronic pain management. In December, Vertex revealed Phase 2 data evaluating Journavx in ...

For Vertex these days, it’s all about the launches ... The measure increases access to non-opioid approaches to pain management in the hospital setting for those enrolled in Medicare.

Vertex’s new drug Journavx (suzetrigine) has been hailed as a scientific breakthrough because it allays pain without entering the brain, minimizing the risk of addiction and dependence that can ...

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor ...

This strategy cemented Vertex's dominance in cystic fibrosis and bodes well for continued growth over the next several years for the management of pain. Vertex appears quite expensive at 900x ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in ... transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical ...